The gene editing therapy invented by Nobel laureates, why did the market only assign a 40% valuation?

A primary school math problem:
CRISPR Therapeutics has a current market value of $4.5 billion. Cash on hand is $2.5 billion. $4.5 billion - $2.5 billion = $2 billion.
What is the market pricing in?
The world's first FDA-approved CRISPR gene editing therapy + 6 active clinical pipelines + Nobel-level intellectual property + exclusive partnership with Vertex valued at $110 billion.
But rebuilding these assets from scratch would cost at least $7.2 billion.
$2 billion vs $7.2 billion. Less than a 30% valuation.
1. What disease does Casgevy treat?
Sickle cell disease (SCD)—patients' red blood cells turn into sickles, blocking blood vessels, causing severe pain, repeated hospitalizations, and organ damage. There are 20 million patients worldwide, with an average lifespan 20-30 years shorter, and lifetime medical costs of $1.6-6 million.
Casgevy’s approach: extract patient’s hematopoietic stem cells → edit a gene with CRISPR/Cas9 → reactivate fetal hemoglobin → re-infuse into the body.
One treatment, curing from the root.
Clinical data: 45/45 SCD patients (100%) experienced no pain crises for 12 months+ after treatment. Longest follow-up over 6 years. Priced at $2.2 million, compared to lifetime treatment costs of $1.6-6 million—a cost-effective deal.
2. Commercialization is accelerating
Casgevy is managed globally by Vertex Pharmaceuticals (market cap of $110 billion, a CF monopoly), with CRSP sharing 40% of profits.
FY2025: global sales of $115.8 million (+10x YoY). Q4 single quarter $54 million, doubling sequentially. 64 patients completed infusion, 301 initiated procedures. Over 75 treatment centers activated.
Analysts project $230-340 million in 2026. William Blair’s peak forecast: $3.6 billion.
3. Not just one product—6 pipelines
Zugo-cel (allogeneic CAR-T): ORR 90%, received FDA RMAT designation. First lupus patient achieved 6 months of complete remission (no medication needed to maintain).
CTX310 (in vivo gene editing): targets cardiovascular diseases, data published in The New England Journal of Medicine—TG reduced by 55%, LDL by 49%. A key step for CRISPR moving from "blood disorders" into the "large cardiovascular market."
CTX211 (Type 1 diabetes): gene-edited stem cell-derived β cells. 8.7 million T1D patients worldwide may no longer need lifelong insulin injections.
4. Cost reset analysis—core
Question: How much does it cost to rebuild a CRISPR Therapeutics from zero?
Key data anchors:
Springer 2023 peer-reviewed study: taking a new cell/gene therapy from clinical stage to FDA approval costs an average of **$2B** (including failure costs + capital costs).
Evernorth estimates higher: average R&D cost for gene therapies is **$5 billion**.
Most critical number: FDA data shows only a 13.8% probability of approval from Phase 1. To reset Casgevy, you need to start 7-8 parallel projects, accounting for 6-7 failures.
Seven asset categories for step-by-step reset:
Asset Conservative Neutral Rebuilding Time
① Casgevy (approved) $2.2B $3.95B 8-12 years
② 6 clinical pipelines $700M $1B 3-8 years
③ GMP manufacturing facilities $140M $200M 2-3 years
④ CRISPR/Cas9 IP + SyNTase $550M $800M Not replicable
⑤ Vertex partnership $600M $800M 3-5 years
⑥ 6 years of clinical data + 75 treatment centers $330M $500M 6-10 years
⑦ 800-person team $100M $150M 2-3 years
Adjusted (including clinical failure risk + time premium + IP non-replicability premium - functional depreciation):
Scenario Reset Cost vs Market Cap $4.5B
Conservative $7.2B 60% premium
Neutral $13.3B 196% premium
Just the neutral cost for Casgevy alone is $3.95 billion, nearly equal to the current total market cap of $4.5 billion. Meanwhile, the implied pipeline value of $2 billion only covers half of Casgevy’s reset cost.
5. Three non-replicable barriers
First, 86% mortality probability has been crossed.
Gene therapies entering Phase 1 have an 86% chance of failure. Casgevy is among the 14% survivors—8 years of development, over $1.1 billion invested by Vertex, countless patient trials. You cannot buy "86% failure does not exist." This is a billion-dollar "realized option."
Second, CRISPR/Cas9 is a Nobel-level invention, impossible to re-invent.
Emmanuelle Charpentier won the 2020 Nobel Prize in Chemistry for discovering CRISPR/Cas9. You can spend money building labs, hiring scientists, conducting clinical trials—but you cannot buy "re-inventing" CRISPR/Cas9. Charpentier’s exclusive licensing of CRSP is a unique IP on Earth.
Third, 6 years of human gene editing safety data is the deepest moat.
For a one-time permanent genome change therapy, the biggest concern is "Is it safe after 10 years?" Casgevy’s 6-year follow-up is the longest globally—each additional day adds an irreplaceable competitive advantage.
6. Risks must be clearly stated
Beam Therapeutics is the most concerning competitor. BEAM-101 base editing does not cause double-strand breaks (theoretically safer), and more importantly, the ESCAPE platform aims to replace chemotherapy preconditioning with antibodies—if successful, it will drastically change the competitive landscape for SCD gene therapy. Casgevy’s biggest current patient barrier is chemotherapy preconditioning (requiring months of prep, long hospital stays, fertility risks).
Commercialization is slower than expected. FY2025: only 64 infusions vs 301 patients initiated, with a conversion rate of about 21%. $2.2 million price + chemotherapy preconditioning = complex reimbursement and treatment process.
Still operating at deep losses. FY2025 net loss of $582 million. $2.5 billion cash provides a 6-7 year runway, but profitability is 5-7 years away.
Short interest ratio is 24.8%—market disagreement is significant.
7. Valuation cross-validation
Median of 10 methods is approximately $65-70 (current $47, +35-50% upside).
17 analysts: 11 buy / 6 hold / 0 sell. Piper Sandler’s target: $110.
ARK’s Woodside holds about 11% of circulating shares (ARKK #2 + ARKG #2), having continuously bought over 800k shares after the March 2026 crash.
Safety margin: $26/share as a bottom (downside protection of 45%).
8. One-sentence summary
The market prices a portfolio worth at least $7.2B to rebuild, at only $1.94B.
86% clinical failure probability has been crossed. Nobel-level IP cannot be re-invented. Six years of safety data deepen the moat daily.
Downside has $26/share cash armor. Upside has a valuation center of $65-70 + dense catalysts.
This is not just a question about CRISPR Therapeutics. It’s about whether you believe in the gene editing revolution.
⚠: This article is solely for personal investment research sharing and does not constitute any investment advice!